Cost-effectiveness of dabigatran etexilate in the prevention of stroke and systemic embolism in patients with atrial fibrillation in Belgium

201336 citationsJournal Articlebronze Open Access

Authors

Hanne Wouters · Boehringer Ingelheim (Belgium)

Vincent Thijs · VIB-KU Leuven Center for Brain & Disease Research

Abstract

This analysis suggests that dabigatran, a novel oral anticoagulant, is a cost-effective treatment for the prevention of stroke and SE in patients with non-valvular AF in the Belgian healthcare setting.

Topics & Keywords

Atrial Fibrillation Management and Outcomes Health Systems, Economic Evaluations, Quality of Life Pharmaceutical Economics and Policy

Publication Details

Published in: Journal of Medical Economics

Volume 16, Issue 3, pp. 407-414

DOI: 10.3111/13696998.2013.766200

Field-Weighted Citation Impact: 4.65

Command Palette

Cost-effectiveness of dabigatran etexilate in the prevention of stroke and systemic embolism in patients with atrial fibrillation in Belgium

Authors

Abstract

Topics & Keywords

Publication Details